Lumity CI Study - Clinical Evaluation of Next Generation Cochlear Implant Sound Processor
Evaluation of Advanced Bionics Next Generation CI Sound Processor Programmed With Target CI v.1.6 Fitting Software in Adult Users of the HiResolution™ Bionic Ear System
This is a prospective within-subjects repeated-measures study that will enroll 18 bilateral adult users implanted with a HiResolution Bionic Ear System (HiRes 90KTM, HiRes 90K TM Advantage, HiResTM Ultra, HiResTM Ultra 3D and CII with HiFocus electrode).
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
The overall goal of this clinical study is to demonstrate the safety and efficacy of next generation sound processor in users of the HiResolution Bionic Ear System. Speech understanding outcomes are expected to be similar with the new sound processor as compared to the Naída CI M90 processor. Therefore, the study uses a non-inferiority design to demonstrate non-inferiority of the next generation processor, relative to the currently approved Naída CI M90 for sentence understanding in quiet and in noise. Additionally, the features on the new device will be evaluated to demonstrate spatial situational awareness using a localization tasks.
Studientyp
Einschreibung (Tatsächlich)
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Ability to provide Informed Consent
- 18 years of age or older
- Bilateral users of a HiResolution™ Bionic Ear System (HiRes 90K™, HiRes 90K™ Advantage, HiRes™ Ultra, HiRes™ Ultra 3D and CII with HiFocus electrode)
- Willingness to participate in all scheduled procedures outlined in the study investigational plan
- Minimum of 6 months of CI experience for each ear
- At least moderate open-set speech recognition abilities with implant in each individual implanted ear, as defined by achieving a score of ≥ 50% words correct in the AzBio Sentence Test in quiet using a Naída CI M90 research processor
- English language proficiency, as determined by the investigator
- Willingness to use a behind-the-ear research processor for the duration of the study
Exclusion Criteria:
- Unrealistic expectations regarding potential benefits, risks and limitations of the investigational device as determined by the investigator
- Unwillingness or physical / cognitive inability of subject to comply with all investigational requirements as determined by the investigator
- < 50% words correct AzBio Sentence Test in quiet in either ear using the Naída CI M90 research processor
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Bilateral Users of a HiResolution Bionic Ear System
Control Device followed by experimental Device. |
Device: Naida M90 sound processor programmed with Target CI v1.5 software Device: Next generation sound processor programmed with investigation software |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Speech Recognition in Quiet
Zeitfenster: 1 Day
|
The primary objective is to demonstrate that speech recognition in quiet on a Next Generation CI sound processor is no worse than speech recognition in quiet on the currently approved Naída CI M90 processor for speech understanding in quiet. Scores are expressed as a percentage of words correct from 0% to 100% with higher scores indicating a better outcome. During the test the subject will be presented with a minimum of 133 words up to a maximum 159. |
1 Day
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CR0124
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .